Eloxx Pharmaceuticals, Inc.
9
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
22.2%
2 terminated/withdrawn out of 9 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
50%
3 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
Role: lead
A Study of ELX-02 in Patients With Alport Syndrome
Role: lead
Phase 1 Study of ELX-02 in Healthy Adults
Role: lead
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
Role: lead
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele
Role: lead
A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02
Role: lead
Phase 1 Study of ELX-02 in Healthy Adult Subjects
Role: lead
A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis
Role: lead
Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers
Role: lead
All 9 trials loaded